

Tetanus




Brief history of disease

- ❑ 5th century BC: **Hippocrates** first **described** the disease
- ❑ 1884: **Carle** and **Rattone** discovered the **etiology** (*cause/origin of disease*)
 - ❑ Produced tetanus by injecting pus from a fatal human case
 - ❑ Nicolaier was able to do the same by injecting soil samples into animals
- ❑ 1889: **Kitasato** **isolated** the organism from human victim, showed that it could produce disease when injected into animals. Reported that **toxin** could be **neutralized** by specific antibodies.
- ❑ 1897: **Nocard** demonstrated the protective effect of **passively transferred antitoxin** → used in WWI
- ❑ 1924: **Descombey** developed tetanus toxoid for **active immunization** → used in WWII

Distribution

In developing countries, neonatal tetanus is a leading cause of neonatal mortality, accounting for over 250,000 deaths annually.

MNT Elimination Status as of December 2002



-  MNT eliminated (135 countries)
-  MNT provisionally eliminated (4 countries)
-  MNT eliminated from over 90% of districts (8 countries)
-  MNT eliminated between 50 - 90% of districts (24 countries)
-  MNT eliminated from less than 50% of districts (21 countries)

It's often called the silent killer, since infants often die before their birth is recorded.


Source: WHO/UNICEF MNT collected data 2002

As of 24 March 2003

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legitimacy of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines indicate approximate boundaries for which there may not yet be full agreement.



Tetanus - United States, 1947-2002




A sharp decrease after tetanus toxoid was introduced into routine childhood immunization in the late 1940s.

All time low in 2002 – 25 cases (0.4 cases in 100,000 population)

* Affects those over the age of 40 the most → is taken to mean that waning immunity is a significant risk factor.

Tetanus – United States, 1980-2002 Age Distribution



India: Burden of disease

- Endemic (high risk, low risk)
- Immunization coverage
- Domestic deliveries by untrained personnel
- Birth customs

- EAG states, medically under-served, livestock raising regions...

-
- High risk areas: preventive measures
 - Low risk areas: surveillance

 - Districts classified:
 - NT incidence
 - Immunization coverage level in preg.
 - Clean delivery by trained person

Hospital records: male preponderance

so, while classifying districts, twice the no.
of reported male cases considered...

Seasonal trend: >50% of annual cases in
months of July – September

Reporting by all hospitals and treatment

facilities: Mandatory


Even nil reporting

To CDHO


Line listing

Causative agent

□ *Clostridium tetani*



Left. Stained pus from a mixed anaerobic infection. At least three different clostridia are apparent.




Right. Electron micrograph of vegetative *Clostridium tetani* cells.

Morphology & Physiology

- ❑ Relatively large, Gram-positive, rod-shaped bacteria
- ❑ Spore-forming, anaerobic.
- ❑ Found in soil, especially heavily-manured soils, and in the intestinal tracts and feces of various animals.
- ❑ Strictly fermentative mode of metabolism.

Virulence & Pathogenicity


- ❑ Not pathogenic to humans and animals by invasive infection but by the production of a potent protein toxin
 - **tetanus toxin** or **tetanospasmin**
 - The second exotoxin produced is tetanolysin—function not known.



Tetanus toxin

- ❑ Produced when spores germinate and vegetative cells grow after gaining access to wounds. The organism multiplies locally and symptoms appear remote from the infection site.
- ❑ One of the three most poisonous substances known on a weight basis, the other two being the toxins of botulism and diphtheria.
 - Tetanus toxin is produced in vitro in amounts up to 5 to 10% of the bacterial weight.
 - Estimated lethal human dose of Tetanospamin = 2.5 nanograms/kg body
- ❑ Because the toxin has a specific affinity for nervous tissue, it is referred to as a **neurotoxin**. The toxin has no known useful function to *C. tetani*.

Tetanus Toxin Transport



- Initially binds to peripheral nerve terminals
- Transported within the axon and across synaptic junctions until it reaches the central nervous system.
- Becomes rapidly fixed to gangliosides at the presynaptic inhibitory motor nerve endings, then taken up into the axon by endocytosis.

- Blocks the release of inhibitory neurotransmitters (glycine and gamma-amino butyric acid) across the synaptic cleft, which is required to check the nervous impulse.
 - If nervous impulses cannot be checked by normal inhibitory mechanisms, it leads to unopposed muscular contraction and spasms that are characteristic of tetanus.

Methods of transmission

- ❑ *C. tetani* can live for years as spores in animal feces and soil. As soon as it enters the human body through a major or minor wound and the conditions are anaerobic, the spores germinate and release the toxins.
- ❑ Tetanus may follow burns, deep puncture wounds, ear or dental infections, animal bites, abortion.
- ❑ Only the growing bacteria can produce the toxin.
- ❑ It is the only vaccine-preventable disease that is *infectious but not contagious* from person to person.

Symptoms

- ❑ Tetanic seizures (painful, powerful bursts of muscle contraction)
- ❑ if the muscle spasms affect the larynx or chest wall, they may cause asphyxiation
- ❑ stiffness of jaw (also called lockjaw)
- ❑ stiffness of abdominal and back muscles
- ❑ contraction of facial muscles
- ❑ fast pulse
- ❑ fever
- ❑ sweating




The back muscles are more powerful, thus creating the arc backward

“Opisthotonus” by Sir Charles Bell, 1809.



Baby has neonatal tetanus with complete rigidity



Clinical Neonatal Tetanus



Clinical Aspects of Neonatal Tetanus

- ***C. tetani* enters through unclean umbilical cord**
- **Signs & Symptoms**
 - **Trismus (risus sardonius)**
 - **Neck stiffness**
 - **Body rigidity**
 - **Opisthotonus**
 - **Convulsions**
 - **Respiratory muscle weakness resulting in death**

Neonatal Tetanus

Any newborn baby that

- sucks and cries normally during the first 2 (two) days of life;
- becomes ill between 3 and 28 days of life with BOTH

1. **Inability to suck**

- and -

2. **Generalized muscle rigidity (stiffness)**

How to Prevent Neonatal Tetanus

Two complimentary strategies

1. Clean delivery - “ 5 cleans”


- **Clean delivery surface**
- **Clean hands**
- **Clean Thread**
- **Clean and New Blade**
- **Clean umbilical cord and stump care**


2. Immunization of mother with TT





**Newborn
showing
risus
sardonicus
and
generalized
spasticity**









CEPHALIC TETANUS : A Rare Form of Localized Tetanus
Courtesy : Google image on tetanus)

Types of tetanus:

local, cephalic, generalized, neonatal

- *Incubation period: 3-21 days, average 8 days.*

Uncommon types:

- **Local tetanus:** persistent muscle contractions in the same anatomic area as the injury, which will however subside after many weeks; very rarely fatal; milder than generalized tetanus, although it could precede it.
- **Cephalic tetanus:** occurs with ear infections or following injuries of the head; facial muscles contractions.

Most common types:

Generalized tetanus

- descending pattern: lockjaw → stiffness of neck → difficulty swallowing → rigidity of abdominal and back muscles.
- Spasms continue for 3-4 weeks, and recovery can last for months
- Death occurs when spasms interfere with respiration.

Neonatal tetanus:

- Form of generalized tetanus that occurs in newborn infants born without protective passive immunity because the mother is not immune.
- Usually occurs through infection of the unhealed umbilical stump, particularly when the stump is cut with an unsterile instrument.

Methods of diagnosis

- ❑ Based on the patient's account and physical findings that are characteristic of the disease.
- ❑ Diagnostic studies generally are of little value, as cultures of the wound site are negative for *C. tetani* two-thirds of the time.
 - When the culture is positive, it confirms the diagnosis of tetanus
- ❑ Tests that may be performed include the following:
 - Culture of the wound site (may be negative even if tetanus is present)
 - Tetanus antibody test
 - Other tests may be used to rule out meningitis, rabies, strychnine poisoning, or other diseases with similar symptoms.

Clinical treatment

- ❑ If treatment is not sought early, the disease is often fatal.
- ❑ The **bacteria** are killed with antibiotics, such as penicillin or tetracycline; further toxin production is thus prevented.
- ❑ The **toxin** is neutralized with shots of tetanus immune globulin, TIG.
- ❑ Other drugs may be given to provide sedation, relax the muscles and relieve pain.
- ❑ Due to the extreme potency of the toxin, immunity does not result after the disease.

Method of prevention - immunization

- ❑ A person recovering from tetanus should begin active immunization with tetanus toxoid (TT) during convalescence.
- ❑ The tetanus toxoid is a formalin-inactivated toxin, with an efficiency of approx. 100%.
- ❑ The **DPT vaccine** includes tetanus, diphtheria and pertussis toxoids; it is routinely given during childhood. After 7 years of age, only TT needs to be administered.
- ❑ Because the antitoxin levels decrease over time, booster immunization shots are needed every 10 years....??

What else can be done?

- ❑ Remove and destroy the source of the toxin through surgical exploration and cleaning of the wound (debridement).
- ❑ Bedrest with a nonstimulating environment (dim light, reduced noise, and stable temperature) may be recommended.
- ❑ Sedation may be necessary to keep the affected person calm.
- ❑ Respiratory support with oxygen, endotracheal tube, and mechanical ventilation may be necessary.

Have you had your Tetanus Shot?



RESOURCES

ENCYCLOPEDIA

- ❑ Breslow, Lester. (2002). "Tetanus." *Encyclopedia of Public Health*. New York : Macmillan Reference USA/Gale Group Thomson Learning.
- ❑ Lederberg, J. (2003) Clostridia. *Encyclopedia of Microbiology*. New York, NY: Academic Press. 1, 834-839.
- ❑ Olendorf, D., et al. (1999). "Tetanus." *The Gale encyclopedia of medicine*. Detroit : Gale Research.

ARTICLES

- ❑ Ahnhert-Hilger, G., Bigalke, H. (1995). "Molecular Aspects of Tetanus and Botulinum Neurotoxin Poisoning." *Progress in Neurobiology*. 46, 83-96.
- ❑ Center for Disease and Control. (2001). "Diphtheria, Tetanus, Pertussis Vaccines: What you need to know." *Vaccine Information Statement 42 U.S.C. §300aa-26*.
- ❑ Clark, D. (2003). "Common acute hand infections." *American Family Physician*. 68, 2167-2177.
- ❑ Humeau, Y., et al. (2000). "How botulism and tetanus neurotoxins block neurotransmitter release." *Biochimie*. 82, 427,446.
- ❑ Zamula, Evelyn. (1996). "Adults need Tetanus Shots, too." *FDA Consumer Magazine*.
http://www.fda.gov/fdac/features/696_tet.html

WEBSITES

- ❑ Todar, K. (2002). The Pathogenic Clostridia. Bacteriology 330 Home page.
<http://www.bact.wisc.edu/Bact330/lecturetetbot>
- ❑ *Clostridium tetani*. (2003). <http://www.historique.net/microbes/tetani.html>
- ❑ Tetanus. <http://www.med.utah.edu/healthinfo/pediatric/Infectious/tetanus.htm>
- ❑ <http://www.nlm.nih.gov/medlineplus/tetanus.html>
- ❑ <http://nfid.org/powerof10/section2/factsheet-tetanus.html>
- ❑ <http://www.who.int/vaccines/en/neotetanus.shtml>
- ❑ <http://www.who.int/vaccines-surveillance/StatsAndGraphs.htm>